The bispecific T cell engager Imdelltra, combined with AstraZeneca’s Imfinzi, extended survival by eight months versus Imfinzi alone in a Phase 3 study testing first-line maintenance—a potentially “practice-changing” outcome, according to Truist analysts. hubs.li/Q04ChrDW0

As part of a strategic reprioritization of its research and development (R&D) activities, Tango Therapeutics plans to let go of about 14% of its workforce, with most of the cuts affecting its research group. hubs.li/Q04ChbdN0

Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said. hubs.li/Q04Ch0x50

As both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is pinning hopes on a smooth finish—and possibly, a result in line with Novartis’ spinal muscular atrophy gene therapy Zolgensma. hubs.li/Q04CgHWK0

CROs cite faster startup timelines, regulatory predictability and tax incentives as reasons for growing interest in Australia. The question remains whether Australia can support drug development at broader scale. hubs.li/Q04CgDvl0

RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved. hubs.li/Q04C93FG0

As part of a strategic reprioritization of its research and development (R&D) activities, Tango Therapeutics plans to let go of about 14% of its workforce, with most of the cuts affecting its research group. hubs.li/Q04C91_t0

Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms set to take effect Jan. 1. hubs.li/Q04C84TW0

Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast. hubs.li/Q04C83KB0

Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor therapy. hubs.li/Q04C7WHJ0

A new proposal from the U.S. government seeking to address investment in Chinese biotech as a matter of national security drew cautious statements from across the industry, with leaders vowing to ensure innovation isn’t stifled. hubs.li/Q04C7WNQ0

After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year. hubs.li/Q04C7FbK0

Roche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones. hubs.li/Q04C78qt0

Troriluzole, in development for spinocerebellar ataxia, was rejected nearly a year ago when the FDA took issue with the design of Biohaven’s registrational study. The FDA agreed to review the application and issue a decision in the first quarter of 2027. hubs.ly/Q04C25TP0

A year after announcing it would lay off up to 500 employees, Ferring Pharmaceuticals is again trimming its workforce. The Switzerland-based pharma has focused its U.S. resources on areas that better support its strategic priorities. hubs.li/Q04C1YLQ0

The sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts in 2021. hubs.ly/Q04C1xlq0

The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in. hubs.li/Q04C0XH-0

Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy. hubs.li/Q04C0VD70

Brepocitinib is on a roll. After its autoimmune skin disease approval, Roivant subsidiary Priovant’s drug hit all primary and secondary endpoints in two Phase 3 non-infectious uveitis trials, leading analysts to note the agent “looked superior to Humira.” hubs.li/Q04C0TlH0

At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Alan Northrup says gets the payload release “just right.” hubs.li/Q04C0HGV0